Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance
Siegfried Kasper, Wiesław Jerzy Cubała, Andrea Fagiolini, et al.
The World Journal of Biological Psychiatry (2020), pp. 1-15
Open Access | Times Cited: 62

Showing 26-50 of 62 citing articles:

The Rapid and Long-Lasting Antidepressant Effects of Iridoid Fraction in Gardenia Jasminoides J.Ellis Are Dependent on Activating PKA-CREB Signaling Pathway
Li Ren, Hailou Zhang, Weiwei Tao, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
A systematic review of the print media representation of ketamine treatments for psychiatric disorders
Nicollette Thornton, Jason Kawalsky, Alyssa Milton, et al.
BJPsych Open (2023) Vol. 9, Iss. 4
Open Access | Times Cited: 7
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment
Luís Gutiérrez-Rojas, Júlia Vendrell-Serres, Josep Antoni Ramos‐Quiroga, et al.
Journal of Psychopharmacology (2024)
Closed Access | Times Cited: 2
Overcoming the myths of esketamine administration: different and not difficult
Florian Buchmayer, Siegfried Kasper
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States
Swapna Karkare, Maryia Zhdanava, Dominic Pilon, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 11, pp. 1432-1448
Closed Access | Times Cited: 10
Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity
Maria Gałuszko‐Węgielnik, Katarzyna Jakuszkowiak‐Wojten, Alina Wilkowska, et al.
The World Journal of Biological Psychiatry (2023) Vol. 24, Iss. 9, pp. 849-853
Closed Access | Times Cited: 5
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder
Thomas Vanicek, Jakob Unterholzner, Rupert Lanzenberger, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 9, pp. 715-718
Closed Access | Times Cited: 8
The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach
Benjamin Spurny‐Dworak, Godber Mathis Godbersen, Murray Bruce Reed, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 8
Is treatment-resistant depression really resistant?
Siegfried Kasper
European Neuropsychopharmacology (2022) Vol. 58, pp. 44-46
Closed Access | Times Cited: 7
Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
Júlia Vendrell-Serres, Óscar Soto-Angona, Amanda Rodríguez‐Urrutia, et al.
Therapeutic Advances in Psychopharmacology (2021) Vol. 11, pp. 204512532110221-204512532110221
Open Access | Times Cited: 8
Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts
João M. Bessa, Serafim Carvalho, Inês B. Cunha, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 6
Hippocampal pituitary adenylate cyclase–activating polypeptide mediates rapid antidepressant-like effects of Yueju pill
Li Ren, Hailou Zhang, Weiwei Tao, et al.
Neuropeptides (2023) Vol. 101, pp. 102350-102350
Open Access | Times Cited: 3
Editorial: Bridging the gap: an interdisciplinary perspective on ketamine in psychiatric disorders
Glenn Hartelius, Sherry-Anne Muscat, Lucie Bartova
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 3
The Importance of Drug Delivery in the Clinical Development and Lifecycle of Drug Products with Examples from Authorised Medicinal Products
Maria Malamatari
Processes (2023) Vol. 11, Iss. 10, pp. 2919-2919
Open Access | Times Cited: 3
Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach
Stefano Pallanti, Joseph Zohar, Siegfried Kasper, et al.
Journal of Psychiatric Research (2023) Vol. 170, pp. 65-72
Closed Access | Times Cited: 3
Gedächtnisambulanzen in Deutschland – strukturell-organisatorische Voraussetzungen und Aufgabenfelder
Lucrezia Hausner, Lutz Frölich, Christine A. F. Von Arnim, et al.
Der Nervenarzt (2020) Vol. 92, Iss. 7, pp. 708-715
Open Access | Times Cited: 8
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression
Amanda J. F. Tamman, Amit Anand, Sanjay J. Mathew
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 745-759
Closed Access | Times Cited: 5
Depression and suicidality severity among TRD patients after 1-year under standard of care: Findings from the TRAL study, a multicenter, multinational, observational study in Latin America
Marco Antônio Caldieraro, Teng Chei Tung, Lina María Agudelo Baena, et al.
Spanish Journal of Psychiatry and Mental Health (2022) Vol. 16, Iss. 2, pp. 85-94
Open Access | Times Cited: 5
Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
Lucie Bartova, Gernot Fugger, Markus Dold, et al.
Journal of Affective Disorders (2023) Vol. 332, pp. 105-114
Open Access | Times Cited: 2
Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel
Nicollette Thornton, Warwick Black, Adrian Bognar, et al.
Asia-Pacific Psychiatry (2023) Vol. 15, Iss. 4
Open Access | Times Cited: 2
Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study
Philip Brenner, Adam Nygren, David Hägg, et al.
International Journal of Psychiatry in Clinical Practice (2021) Vol. 26, Iss. 3, pp. 251-258
Open Access | Times Cited: 5
An electrophysiological model of major depression: Relevance to clinical subtyping and pharmacological management
Ivo H. Cerda, Paul J. Fitzgerald
Psychiatry Research (2021) Vol. 303, pp. 114054-114054
Closed Access | Times Cited: 4
Recommendations for treatmenf of unipolar depressive disorder
Anja Plemenitaš Ilješ, Maja Drobnič Radobuljac, Blanka Kores Plesničar, et al.
Slovenian Medical Journal (2023), pp. 1-16
Open Access | Times Cited: 1
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Nahida Nayaz Ahmed, Faisal Albishi, Suhail Ahmad Khan, et al.
Middle East Current Psychiatry (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Research Progress of Esketamine in Improving Perioperative Depression and Sleep Quality
永旭 高
Advances in Clinical Medicine (2024) Vol. 14, Iss. 07, pp. 1073-1078
Closed Access

Scroll to top